NCT00268918View on ClinicalTrials.gov

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2011

Conditions
Ovarian CancerEndometrial CancerCervical CancerFallopian Tube CancerPeritoneal CancerBreast Cancer
Interventions
DRUG

Docetaxel

Participants may continue receiving study drug as long as their disease does not worsen

DRUG

PTK787

Participants may continue receiving study drug as long as their disease does not worsen

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00268918 - Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | Biotech Hunter | Biotech Hunter